Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study

Othman Al-Sawaf*, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna-Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivcheva, Carsten Utoft Niemann, Anthony P Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S Manzoor, Dureshahwar Jawaid, Nnadozie EmechebeJacob Devine, Michelle Boyer, Eva D Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael J Hallek, Kirsten Fischer

*Corresponding author af dette arbejde

Fingeraftryk

Dyk ned i forskningsemnerne om 'Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study'. Sammen danner de et unikt fingeraftryk.

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science